CLINICAL_TRIALS
trial_result
· 2011-11-17
Clinical Trial Update: Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma [Phase 4]
Summary
Phase 4 trial evaluating the effect of omalizumab on markers of asthma impairment in patients with persistent allergic asthma; results were posted in 2011.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Persistent Allergic Asthma | Phase 4 | Status: COMPLETED | Results posted: 2011-11-17